What Is Traumatic Hemorrhage of the Cerebrum?

Traumatic hemorrhage of the cerebrum is bleeding within the brain tissue itself, triggered by a blow or jolt to the head. It is one of several types of traumatic intracranial hemorrhage, and it carries serious risks because blood pooling inside brain tissue raises pressure in the skull, damages surrounding neurons, and can expand over the hours and days after injury. Falls and motor vehicle crashes account for most cases, and the people most vulnerable include the very young, adolescents and young adults, and the elderly.

What Causes It and How the Brain Gets Damaged

The immediate cause is mechanical force applied to the head. When the skull accelerates or decelerates sharply, the brain moves inside it, and the mismatch in motion can tear blood vessels embedded in brain tissue. It is well established that cerebral blood vessels commonly tear and bleed as a direct consequence of traumatic brain injury. But even vessels that do not rupture outright may experience significant stretching that damages their walls, altering both their structure and function in ways that set the stage for delayed problems.¹

Globally, falls and road injuries are the most important causes of nonfatal traumatic brain injury, while road traffic crashes remain the leading cause of death among people aged 15 to 29.² In older adults, the picture has shifted: ground-level falls, the kind that happen stepping off a curb or tripping on a rug, have become the leading cause of head injury in that age group.³ That may seem surprising, but it makes sense once you consider how the aging brain becomes more vulnerable to even minor impacts.

Why Older Adults Are at Elevated Risk

As people age, the brain gradually shrinks, leaving a wider gap between the brain surface and the inner wall of the skull. That extra space allows the brain to move more freely during an impact, which stretches the bridging blood vessels that span the gap. Computational simulations show that relative displacement between the brain and skull increases with worsening atrophy, especially in the frontal and occipital regions. Even when researchers modeled a 50 percent reduction in impact force, vascular damage still occurred in elderly models.⁴ Mechanical testing of bridging veins also showed roughly a 50 percent decline in their ultimate stress and a 35 percent decline in their ultimate strain with advancing age, meaning those vessels simply cannot stretch as far before breaking.

A separate retrospective study found that intracranial hemorrhage after trauma correlated strongly with cortical atrophy and ventricular width, reinforcing the idea that a shrinking brain is more susceptible to bleeding.⁵ The practical takeaway is that a seemingly trivial fall in an older person should not be dismissed. Among older adults who sustain a head injury from a ground-level fall, about 7 percent turn out to have a traumatic intracranial hemorrhage.⁶

How Blood in the Brain Causes Secondary Damage

The initial bleed is only the beginning. Once blood pools in brain tissue, a cascade of toxic processes unfolds. Hemoglobin and its breakdown products, including heme, hemin, and free iron, damage cell membranes through a process called lipid peroxidation, generate reactive oxygen species, and make surrounding cells more sensitive to further injury. The result is swelling, cell death, and increased harm beyond the area of the original bleed.⁷ This secondary injury is a major reason why outcomes can worsen in the days after an initial traumatic cerebral hemorrhage, even if the original bleed seemed relatively contained.

The Anticoagulant Problem

Millions of people take blood-thinning medications for conditions like atrial fibrillation or a history of blood clots. When one of these patients suffers a traumatic brain bleed, the medication that prevents clots in other settings makes it harder for the brain to stop bleeding. Whether newer direct oral anticoagulants (DOACs) are safer in this context than older vitamin K antagonists like warfarin is an active area of research, and the data are not entirely consistent.

One study found that the rate of hemorrhage expansion or new bleeding was similar between patients on DOACs and those on warfarin-type drugs: about 11 percent versus roughly 15 percent, with no statistically significant difference.⁸ However, a separate study reported the opposite pattern, finding that newer oral anticoagulants were associated with a higher rate of hematoma expansion compared with vitamin K antagonists or compared with patients whose clotting was normal.⁹ The conflicting results likely reflect differences in study populations and sample sizes, but the practical point is clear: any anticoagulant raises the stakes when the brain starts bleeding.

When a patient on blood thinners shows up with a brain bleed, the priority is reversing the anticoagulant effect as quickly as possible. A meta-analysis of 32 studies covering over 1,800 patients found that the main reversal agents achieved successful anticoagulation reversal in roughly three-quarters to four-fifths of cases. The agent idarucizumab, which specifically reverses the DOAC dabigatran, had the highest reversal rate at about 82 percent and the lowest all-cause mortality at about 11 percent. By contrast, four-factor prothrombin complex concentrate and andexanet alfa had mortality rates closer to a quarter of patients.¹⁰ Those mortality numbers reflect the severity of the injury, not just the reversal agent’s effectiveness, but they give a sense of how dangerous anticoagulant-associated brain bleeds remain.

Controlling Pressure Inside the Skull

The skull is a closed box. When blood or swelling takes up extra space inside it, pressure rises and can squeeze healthy brain tissue, cutting off its blood supply. Managing this intracranial pressure is central to acute care for traumatic cerebral hemorrhage, and two osmotic agents, mannitol and hypertonic saline, are workhorses of that effort. A systematic review found that mannitol reduced intracranial pressure slightly more in absolute terms, but three percent hypertonic saline was more effective at maintaining cerebral perfusion pressure and had a longer-lasting effect on pressure reduction.¹¹

In children with severe traumatic brain injury, hypertonic saline outperformed mannitol for pressure reduction when intracranial pressure was dangerously elevated. The advantage was especially pronounced at higher pressure thresholds, and remained significant even after adjusting for other variables when pressure exceeded 25 mmHg.¹² The clinical reality is that many centers use both agents depending on the situation, and the evidence suggests neither is clearly superior across all scenarios.

Whether continuously monitoring intracranial pressure with an implanted sensor improves outcomes is, somewhat surprisingly, still debated. One cohort study found that monitored patients had better rates of good recovery and favorable outcomes compared to unmonitored patients.¹³ But a larger comparative effectiveness study showed worse six-month recovery among monitored patients, with good recovery in only about 12 percent of monitored patients versus 19 percent of unmonitored patients. Monitored patients also received more medical therapies, which may itself carry risks.¹⁴ This likely reflects selection bias: patients whose injuries are severe enough to warrant a monitor are already in worse shape. The debate is not whether intracranial pressure matters, but whether the act of monitoring and the treatments it triggers consistently lead to better outcomes.

Surgical Options

When a traumatic cerebral hemorrhage is large enough or expanding fast enough to threaten life, surgery becomes necessary. The two main open approaches are craniotomy, where a piece of skull is temporarily removed to access and evacuate the blood clot and then replaced, and decompressive craniectomy, where the bone flap is left off to give the swollen brain room to expand outward. A study comparing the two approaches for hemorrhagic contusions found that the craniectomy group had lower mortality (about 13 percent vs. 25 percent), a much lower reoperation rate (about 8 percent vs. 38 percent), and better functional scores at six months.¹⁵

That said, the picture is not so simple in the most severe cases. A study of ultra-early decompressive craniectomy in patients with devastating injuries found an overall mortality rate of about 69 percent, with only about 5 percent achieving a good outcome. The timing of the craniectomy did not significantly change outcomes compared with the control group.¹⁶ The lesson here is that surgery can help when the brain has a reasonable chance of recovery, but it cannot overcome catastrophic damage. Age also matters: patients over 65 and those with worse neurological status on arrival have independently worse outcomes after surgery regardless of the procedure chosen.¹⁷

Minimally invasive techniques are gaining traction. A retrospective cohort study found that minimally invasive hematoma evacuation offered advantages over craniotomy for certain patients, including less surgical trauma, more complete clot removal, and fewer complications, all of which supported better neurological recovery.¹⁸ Endoscopic-assisted removal, where a small camera and instruments are inserted through a narrow opening, has also shown promise in case reports, with one patient discharged just 48 hours after surgery and alert within two weeks.¹⁹ These less-invasive approaches are especially interesting because the traditional open procedures carry significant morbidity of their own.

Preventing Blood Clots Without Restarting the Bleed

Here is a genuine dilemma that clinicians face every day: patients with traumatic brain hemorrhage are at high risk for blood clots in the legs and lungs because they are immobile, injured, and often in intensive care. But giving them blood-thinning medication to prevent those clots could theoretically make the brain bleed worse. The timing of when to start that preventive treatment has been a contentious question.

Evidence increasingly supports starting blood clot prevention early. A large prospective multicenter study found that patients who received pharmacologic clot prevention within 48 hours had lower rates of venous blood clots (about 7 percent vs. 12 percent for those who started later) without any increase in brain hemorrhage progression. On multivariate analysis, delaying clot prevention beyond 48 hours nearly doubled the odds of a clot.²⁰ A separate propensity-matched study in patients with severe traumatic brain injury reached the same conclusion: early initiation of clot prevention was associated with decreased risk of blood clots without increased risk of delayed neurosurgical intervention or death.²¹

Seizure Prevention

Traumatic brain bleeds irritate surrounding brain tissue, and that irritation can trigger seizures in the early days after injury. Most trauma centers prescribe an anti-seizure drug as a preventive measure. Levetiracetam has become the most commonly used medication for this purpose, partly because it has fewer drug interactions than older options like phenytoin. At one level II trauma center, confirmed post-traumatic seizures occurred in about 2 percent of patients receiving levetiracetam, with early seizures happening in under 1 percent.²²

Whether levetiracetam is actually superior to phenytoin or even to no medication at all remains unclear. A systematic review and meta-analysis comparing the two drugs found no clear difference in the incidence of seizures in the first week after severe traumatic brain injury.²³ Another meta-analysis found no significant differences in seizure events between levetiracetam and no anti-seizure medication at all, nor between levetiracetam and other prophylactic drugs.²⁴ The reason clinicians keep prescribing it despite this uncertain evidence is that post-traumatic seizures can cause real harm, and levetiracetam’s side-effect profile is relatively mild. It is a judgment call made under uncertainty.

Traumatic Cerebral Hemorrhage in Children

Children are not simply small adults when it comes to brain injuries. Their skulls are thinner and more deformable, their brains have a higher water content, and the mechanisms of injury often differ, with abuse being a significant cause in infants. A study of 79 children treated at a level 1 trauma center for traumatic intracerebral hemorrhage found that those with multiple injuries, worse initial neurological status, and higher injury severity scores were significantly more likely to need surgical treatment.²⁵

An older study of 314 children with head injuries identified 21 who had isolated traumatic hemorrhage within the brain and classified them into three types based on their clinical course and imaging. Most were managed without surgery, but the outcomes were mixed: good recovery in one patient, fair recovery in seven, poor recovery in two, and two deaths. The most severe type had the worst prognosis.²⁶ One practical difference in pediatric care is the choice of pressure-lowering agents: as noted earlier, hypertonic saline tends to outperform mannitol in children at higher intracranial pressure thresholds.

Blood Biomarkers and Faster Diagnosis

A CT scan of the head remains the standard for identifying traumatic brain hemorrhage. But getting a CT scan takes time, and in some settings, a scanner may not be immediately available. Blood-based biomarkers are an active area of research that could change how quickly a brain bleed is detected. Proteins like glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), S100B, and neurofilament light chain reflect different types of brain cell damage and can be measured from a simple blood draw.²⁷

Among these, GFAP has shown the most promise for detecting intracranial hemorrhage specifically. When added to standard prehospital clinical information, GFAP significantly improved the ability to predict intracranial hemorrhage, 48-hour mortality, and 28-day mortality in patients with moderate or severe traumatic brain injury.²⁸ The eventual goal is a rapid, field-deployable blood test that paramedics could use to triage patients before they arrive at the hospital, routing those with likely brain bleeds directly to facilities equipped for neurosurgery.

Long-Term Recovery and What to Expect

Surviving the acute phase is one thing; returning to normal life is another. A study following patients years after moderate to severe traumatic brain injury found that only about 29 percent were working full time. The most persistent limitations showed up in complex daily activities like managing money and shopping, and these limitations correlated with residual cognitive impairment.²⁹

For older adults who were taking anticoagulants or antiplatelet drugs before their injury, the long-term picture is grimmer. Even when the initial bleed appears relatively mild, preinjury use of warfarin or clopidogrel is associated with an increased risk of unfavorable long-term neurological outcomes compared with similar patients who were not on these medications.³⁰ This means that a mild-appearing brain bleed in a 78-year-old on blood thinners deserves more aggressive follow-up than the initial imaging might suggest.

The Difficult Conversation About Withdrawing Life Support

In the most severe traumatic brain injuries, families and medical teams face agonizing decisions about whether to continue aggressive treatment. These decisions have real consequences for the data we use to guide care. A systematic review of clinical trials in severe traumatic brain injury found that withdrawal of life-sustaining therapy was reported in only about 20 percent of trials, but in those trials that did report it, roughly 63 percent of deaths were associated with the decision to withdraw treatment.³¹ That means the outcomes we see in trials are shaped not only by the injuries themselves, but by the human decisions made about continuing care.

A Canadian multicenter cohort study found that a high proportion of early deaths after severe traumatic brain injury were associated with the withdrawal of life-sustaining therapy. Given the limited accuracy of current prognostic tools, the study authors cautioned against early withdrawal decisions.³² This creates a troubling feedback loop: if patients who might have recovered are allowed to die because early prognosis is uncertain, then the mortality statistics from which future prognoses are drawn will be pessimistically skewed. No one has fully solved this problem, and it is one of the most ethically fraught aspects of neurotrauma care.

How Surgical Thinking Has Changed

The history of surgery for traumatic brain hemorrhage tracks the broader evolution of neurosurgery. Historically, the emphasis was on opening the skull primarily for diagnostic purposes, to find out what was going on inside. With the arrival of CT scanning in the 1970s, the diagnostic role of surgery faded, and the focus shifted to decompression, maintaining adequate blood flow to the brain, restoring normal anatomy, preventing complications, and preserving cosmesis.³³ Today, advances in understanding the biology of hemorrhagic traumatic brain injury and the development of minimally invasive and endoscopic techniques are prompting a fresh reexamination of when, how, and on whom to operate.³⁴ Much of current surgical practice still rests on retrospective studies and surgeon preference rather than randomized trials, which means the field is overdue for more rigorous evidence on the questions that matter most to patients and families.